RVTYHealthcare · Diagnostics & ResearchThe 18 Wall Street analysts covering Revvity, Inc. hold a median 12-month price target of $160 — +0.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 4 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Revvity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (98): The share count has been shrinking and the company is not leaning on new borrowing.
Quality (58): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (11): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on RVTY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +0.3% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $130 → $175 |
| 7 Oct 2026 | Barclays | Maintains | Equal-Weight | $115 → $160 |
| 6 Oct 2026 | William Blair | Initiates | Outperform | — |
| 9 Sept 2026 | UBS | Assumes | Neutral | $120 → $140 |
| 4 Sept 2026 | Keybanc | Maintains | Overweight | — |
| 4 Sept 2026 | Keybanc | Maintains | Overweight | $125 → $165 |
| 1 Sept 2026 | RBC Capital | Initiates | Sector Perform | — |
| 1 Sept 2026 | RBC Capital | Initiates | Sector Perform | $135 |
| 5 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $125 → $126 |
| 5 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $110 → $125 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 26 June 2026 | Bernstein | Reinstates | Market Perform | $115 |
| 2 June 2026 | Wolfe Research | Assumes | Peer Perform | — |
| 7 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 6 May 2026 | JP Morgan | Maintains | Neutral | — |
| 6 May 2026 | Stifel | Maintains | Hold | — |
| 6 May 2026 | TD Cowen | Maintains | Buy | — |
| 4 May 2026 | Baird | Maintains | Outperform | — |
| 14 Apr 2026 | Barclays | Downgrade | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RVTY appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Revvity, Inc. returned +74.4% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 10% of US stocks
Cheaper than 19% of US stocks
Cheaper than 35% of US stocks
Cheaper than 11% of US stocks
Higher than 30% of US stocks
Higher than 32% of US stocks
Higher than 70% of US stocks
Higher than 75% of US stocks
Higher than 66% of US stocks
Higher than 50% of US stocks
Higher than 61% of US stocks
Higher than 63% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Revvity, Inc. has a market value of $18.2B and an enterprise value of $20.6B.
Revenue in the twelve months to 30 June 2026: $2.9B. The latest quarter grew 1.3% year on year.
Net income over the same four quarters: $237.6M, a 8.2% net margin.
Diluted earnings per share, trailing twelve months: $2.09.
Free cash flow in the twelve months to 30 June 2026: $558.1M, after $69.5M of capital spending.
Revvity, Inc. spent $475.8M on share buybacks and $31.7M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 72.7×; forward P/E: 27.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.17%, paying out 13% of earnings.
Revvity, Inc. employs 11,000 people — $265K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Revvity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Revvity reported third-quarter results that exceeded its expectations, supported by stronger demand in Life Sciences, continued growth in Diagnostics, and expanding interest in AI-related research tools.
Why it matters — The results and cited business trends provide RVTY watchers with an update on demand across the company’s segments and research tools.
Seeking Alpha published a transcript of Revvity, Inc.’s Q3 2026 earnings call. The excerpt provides no details about the company’s results or management commentary.
Why it matters — The transcript may be relevant to RVTY watchers seeking the company’s Q3 2026 earnings-call discussion, but the supplied excerpt contains no specific information to assess.
Revvity reported Q3 2026 earnings and revenue above estimates, citing Life Sciences growth and margin expansion. The company raised its annual outlook.
Why it matters — The results and higher annual outlook provide RVTY watchers with an update on business performance and management expectations.
Revvity reported strong third-quarter results and a heightened 2026 outlook, amid elevated investor expectations. The report was accompanied by a surge in the stock.
Why it matters — The results and updated outlook are relevant to RVTY watchers assessing the company’s latest performance and expectations.
Revvity reported Q3 earnings of $1.38 per share, above the Zacks Consensus Estimate of $1.29. Earnings were $1.18 per share a year earlier.
Why it matters — The report gives RVTY watchers an update on quarterly earnings relative to analyst estimates and the prior-year quarter.
The 18 Wall Street analysts covering Revvity, Inc. have a median 12-month price target of $160, with estimates ranging from $110 to $175. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering Revvity, Inc., 6 rate it a Buy, 11 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Revvity, Inc. 96 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Revvity, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (98 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +0.3% from the last close, and Ticker Nerd's factor model ranks Revvity, Inc. 96 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Revvity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RVTY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $110 to $175 over the next 12 months.
Revvity, Inc. returned +74.4% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Revvity Inc. is a global life sciences and diagnostics company that provides health science solutions, technologies, and services for research, development, and clinical testing.
The most recent item we track (MarketBeat, 4 Nov 2026): "Revvity Q3 Earnings Call Highlights". Revvity reported third-quarter results that exceeded its expectations, supported by stronger demand in Life Sciences, continued growth in Diagnostics, and expanding interest in AI-related research tools.
Revvity Inc. is a global life sciences and diagnostics company that provides health science solutions, technologies, and services for research, development, and clinical testing. Revvity’s current business is organized around two main segments: Life Sciences, which supplies reagents, instruments, and software to support biopharma and academic research; and Diagnostics, which offers assay platforms, instruments, and software for reproductive health, immunodiagnostics, newborn screening, applied genomics, and infectious disease testing. The company also focuses on translational multi-omics, biomarker identification, imaging, screening, detection, and informatics, helping customers move biological data through connected laboratory workflows. Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations across global markets. Headquartered in Waltham, Massachusetts, Revvity plays an important role in enabling scientific discovery and supporting clinical decision-making across the healthcare and research ecosystem.
CEO Dr. Prahlad R. Singh Ph.D. · 11,000 employees · United States · https://www.revvity.com
